DPEP-1 Binding Compositions for Tissue-Specific Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel therapeutic compounds to modulate inflammation and block leukocyte recruitment, inhibit tumor metastasis, and treat conditions such as acute kidney injury and sepsis, as existing anti-inflammatory agents often cause serious side effects and are not tissue-specific.
Innovation Solution
Compositions and methods involving DPEP-1 binding agents, including peptides and small molecules, that bind to DPEP-1 to reduce inflammation, block leukocyte recruitment, and inhibit tumor metastasis, administered via parenteral routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-inflammatory agents are used to reduce inflammation and block leukocyte recruitment, then the inflammatory response is suppressed, but serious side effects occur and tissue specificity is lost
Solution Approach 1:
The patent applies local quality by designing DPEP-1 binding agents that specifically target DPEP-1 expressed on endothelial cells at sites of inflammation. This enables selective suppression of inflammatory leukocyte recruitment at affected tissues while preserving normal physiological functions in healthy tissues, thereby reducing systemic side effects while maintaining anti-inflammatory efficacy.
2Reliability
If existing anti-inflammatory agents are used to block leukocyte recruitment, then inflammation is reduced, but the agents lack tissue specificity
Solution Approach 1:
The DPEP-1 binding agents exhibit local quality by specifically binding to DPEP-1 on endothelial cells at inflammatory sites. This targeted approach provides tissue specificity, allowing the agents to act selectively where DPEP-1 is upregulated during inflammation while leaving other tissues unaffected.
3Object-affected harmful factors
If DPEP-1 binding agents are used to achieve tissue-specific anti-inflammatory action, then side effects are minimized, but novel therapeutic compounds are required
Solution Approach 1:
The patent employs copying by creating synthetic peptides and small molecules that replicate the binding properties of natural DPEP-1 ligands. These copied molecular structures provide the desired tissue-specific anti-inflammatory action while being synthetically producible, thus resolving the challenge of making novel therapeutic compounds available through established pharmaceutical manufacturing processes.
Data Source
AI summary
Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.